Eli Lilly and Company gained at the open of trade Thursday after the pharma firm said it would carry out a series of changes to its organization and leadership structure to “better align them with the company’s growth opportunities.”
Christi Shaw has been hired to lead the company’s Bio-Medicines business beginning April 3. Shaw will succeed David A. Ricks, who became Lilly’s president and CEO on January 1, as senior vice president and president of Lilly Bio-Medicines.
Beginning on February 1, Lilly’s Diabetes, Oncology and Bio-Medicines human pharmaceutical therapeutic business areas will assume commercial responsibility for their products in China, in addition to the U.S., Japanese and Canadian markets in which they already operate.
By Travis Berry